These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1393 related items for PubMed ID: 23993928

  • 1. Dual trigger with combination of gonadotropin-releasing hormone agonist and human chorionic gonadotropin significantly improves the live-birth rate for normal responders in GnRH-antagonist cycles.
    Lin MH, Wu FS, Lee RK, Li SH, Lin SY, Hwu YM.
    Fertil Steril; 2013 Nov; 100(5):1296-302. PubMed ID: 23993928
    [Abstract] [Full Text] [Related]

  • 2. Dual trigger with gonadotropin-releasing hormone agonist and standard dose human chorionic gonadotropin to improve oocyte maturity rates.
    Griffin D, Feinn R, Engmann L, Nulsen J, Budinetz T, Benadiva C.
    Fertil Steril; 2014 Aug; 102(2):405-9. PubMed ID: 24842671
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
    Bodri D, Guillén JJ, Galindo A, Mataró D, Pujol A, Coll O.
    Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders.
    Griffin D, Benadiva C, Kummer N, Budinetz T, Nulsen J, Engmann L.
    Fertil Steril; 2012 Jun; 97(6):1316-20. PubMed ID: 22480822
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Is the effect of premature elevated progesterone augmented by human chorionic gonadotropin versus gonadotropin-releasing hormone agonist trigger?
    Connell MT, Patounakis G, Healy MW, DeCherney AH, Devine K, Widra E, Levy MJ, Hill MJ.
    Fertil Steril; 2016 Sep 01; 106(3):584-589.e1. PubMed ID: 27178228
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols.
    Farhi J, Ben-Haroush A, Lande Y, Sapir O, Pinkas H, Fisch B.
    Fertil Steril; 2009 Feb 01; 91(2):377-82. PubMed ID: 18321490
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection.
    Qin N, Chen Q, Hong Q, Cai R, Gao H, Wang Y, Sun L, Zhang S, Guo H, Fu Y, Ai A, Tian H, Lyu Q, Daya S, Kuang Y.
    Fertil Steril; 2016 Aug 01; 106(2):334-341.e1. PubMed ID: 27114329
    [Abstract] [Full Text] [Related]

  • 15. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.
    Youssef MA, Van der Veen F, Al-Inany HG, Mochtar MH, Griesinger G, Nagi Mohesen M, Aboulfoutouh I, van Wely M.
    Cochrane Database Syst Rev; 2014 Oct 31; 2014(10):CD008046. PubMed ID: 25358904
    [Abstract] [Full Text] [Related]

  • 16. Is the modified natural in vitro fertilization cycle justified in patients with "genuine" poor response to controlled ovarian hyperstimulation?
    Kedem A, Tsur A, Haas J, Yerushalmi GM, Hourvitz A, Machtinger R, Orvieto R.
    Fertil Steril; 2014 Jun 31; 101(6):1624-8. PubMed ID: 24680364
    [Abstract] [Full Text] [Related]

  • 17. Dual trigger with the combination of gonadotropin-releasing hormone agonist and standard dose of human chorionic gonadotropin improves in vitro fertilisation outcomes in poor ovarian responders.
    Mutlu I, Demirdag E, Cevher F, Erdem A, Erdem M.
    J Obstet Gynaecol; 2022 Jul 31; 42(5):1239-1244. PubMed ID: 34565274
    [Abstract] [Full Text] [Related]

  • 18. Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles.
    Lee JR, Kim SH, Kim SM, Jee BC, Ku SY, Suh CS, Choi YM, Kim JG, Moon SY.
    Fertil Steril; 2008 Apr 31; 89(4):860-7. PubMed ID: 18249372
    [Abstract] [Full Text] [Related]

  • 19. Combined administration of gonadotropin-releasing hormone agonist with human chorionic gonadotropin for final oocyte maturation in GnRH antagonist cycles for in vitro fertilization.
    Kim CH, Ahn JW, You RM, Kim SH, Chae HD, Kang BM.
    J Reprod Med; 2014 Apr 31; 59(1-2):63-8. PubMed ID: 24597289
    [Abstract] [Full Text] [Related]

  • 20. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN, Ho MT, Ha TD, Phung HT, Huynh GB, Humaidan P.
    Fertil Steril; 2016 Feb 31; 105(2):356-63. PubMed ID: 26523330
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 70.